Effects of the LysulinTM supplementation on pre-diabetes: A randomized double-blind, placebo-controlled clinical trial

Dr. Jhon Burd0 个研究点开始时间: 待定最近更新: 2024年8月20日

适应症

试验速览

暂无简介。

•a) Age between 18-60 years
•b) Both male and female
•c) Screening test confirming presence of pre-diabetes as defined by Fasting Plasma Glucose (FPG) between 100-125mg/dl (Impaired Fasting Glucose [IFG]) or 2-hr Post Oral Glucose Tolerance Test (OGTT) Plasma Glucose between 140-199mg/dl (Impaired Glucose Tolerance [IGT]) or both IFG and IGT or a HbA1c value between 6.0-6.4%.

•1. On any other vitamin or mineral supplementation
•2. The current use of a weight loss medicine or dietary modification
•3. History of diabetes mellitus
•4. Presently having acute diseases requiring treatment (too numerous and diverse to be named individually)
•5. Impaired hepatic or renal functions
•6.Patients with any malignancy or any other unrelated chronic illness, such as chronic kidney disease, ischaemic heart disease. Etc (again too numerous and diverse to be named individually)
•7.Patients with cardiac, liver or respiratory failure
•8.Any condition in the opinion of the primary investigator that would contraindicate the patient's participation
•9.Allergy to any of the constituents of the investigational tablets.
•10.Lactation
•11.Pregnancy
•12.Unwillingness to use an effective form of birth control for women of child bearing years.

发起方

Dr. Jhon Burd